Mersana Therapeutics Inc.’s stock cratered on Thursday, after the U.S. Food and Drug Administration paused enrollment in two trials of a treatment for ovarian cancer after patients suffered bleeding events and five died.
The stock MRSN tumbled 58% to mark its biggest ever one-day percentage decline since the company went public in June of 2018.
Cambridge,…
This post was originally published on Market Watch
